First‐line envafolimab plus recombinant human‐endostatin in advanced non–small cell lung cancer with PD‐L1 tumor proportion score ≥1% (Endouble): A multicenter, prospective, single‐arm, phase 2 trial
Authors:
Open Access
Abstract
Background: This trial evaluates the efficacy and safety of combining envafolimab and recombinant human endostatin (Rh‐endostatin) in advanced non–small cell lung cancer (NSCLC). Methods: This trial included treatment‐naive advanced patients with NSCLC with programmed death‐ligand 1 (PD‐L1)–positive and no driver gene mutations. All patients received treatment with envafolimab and Rh‐endostatin every 21 days until disease progression or intolerable toxicity. The primary end points were objective response rate (ORR) and safety. Secondary end points included progression‐free survival (PFS), overall survival (OS), disease control rate (DCR), and duration of response (DOR). An exploratory analysis was conducted to identify biomarkers associated with treatment efficacy. Results: A total of 33 patients were included for efficacy and safety analysis. The ORR was 48.5% (95% CI, 30.8%–66.5%), and the DCR was 81.8% (95% CI, 64.5%–93.0%). The median PFS was 12.3 months (95% CI, 3.1 months–21.5 months). With a median follow‐up of 13.9 months, the median OS was not reached, and the 1‐year OS rate was 73.9%. Treatment‐related adverse events (TRAEs) were observed in 25 (75.8%) patients. Grade ≥3 TRAEs were observed in six patients, and there were no grade 4 or 5 AEs. Based on plasma proteomic analysis, receiver operator characteristic analysis yielded area under the curve (AUC) values of 0.77 (95% CI, 0.61–0.93) for MMP1 and 0.68 (95% CI, 0.49–0.87) for TNFRSF6B. The combined model demonstrated an AUC of 0.81 (95% CI, 0.66–0.96). Conclusions: Envafolimab combined with Rh‐endostatin demonstrated favorable efficacy and tolerable toxicity in patients with PD‐L1–positive, advanced driver‐gene negative NSCLC.Keywords
This publication has 21 references indexed in Scilit:
- Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 TrialJournal of Thoracic Oncology, 2023
- Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation BurdenJAMA Oncology, 2023
- Efficacy and safety of recombinant human endostatin combined with whole-brain radiation therapy in patients with brain metastases from non-small cell lung cancerRadiotherapy and Oncology, 2022
- IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLCJournal of Thoracic Oncology, 2021
- Evaluation and analysis of incidence and risk factors of lower extremity venous thrombosis after urologic surgeries: A prospective two-center cohort study using LASSO-logistic regressionInternational Journal of Surgery, 2021
- Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLCJournal of Thoracic Oncology, 2021
- Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLCJournal of Thoracic Oncology, 2021
- The TNF–TNFR Family of Co-signal Molecules2019
- Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung CancerJAMA Oncology, 2018
- Structural basis of a novel PD-L1 nanobody for immune checkpoint blockadeCell Discovery, 2017